The best Side of "3
All enrolled clients who obtained at least one particular dose of zosuquidar or placebo for the duration of induction were being monitored for the occurrence of adverse occasions (439 sufferers, 219 on zosuquidar and 210 on placebo). The commonest adverse events were related to the period of extended and substantial myelosuppression as is anticipat